Back to Peptides
Livagen
Anti-Aging & DNA RegulationLivagen is a thymic-derived short peptide with powerful gene-regulatory effects. It stabilizes chromatin, promotes DNA repair, and enhances immune signaling, particularly in aging individuals. It is studied for its epigenetic role in longevity and tissue regeneration.
Reconstitute
3 mL BAC + 20mg vial
67 mcg/unit
Daily Range
5–20 mcg Subcutaneous (SQ)
Daily
Standard Dose
10 mcg
Cycle
4–8 weeks
then reassess
Livagenthymic peptideDNA repairchromatin stabilizationimmune support
Dosing & Reconstitution Guide
Preclinical protocols range from 100–200 μg daily over 10–15 days. These studies are not sufficient for therapeutic claims.
Standard / Gradual Approach
20mg VialstandardPhaseDoseVolume
Weeks 1–20.5 mg (500 mcg)7.5 units (0.075 mL)
Weeks 3–41.0 mg (1000 mcg)15 units (0.15 mL)
Weeks 5–61.5 mg (1500 mcg)22.5 units (0.225 mL)
Weeks 7–122.0 mg (2000 mcg)30 units (0.30 mL)
Protocol Summary
Subcutaneous (SQ): Daily · Dose range 5–20 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Inject daily for 20–30 days. Repeat every 6–12 months depending on aging or immune protocols.
🧪 Quick Start
Vial Size
20 mg
BAC Water
3 mL
Concentration
6.67 mcg/unit
Starting Dose
0.5 mg (500 mcg) (7.5 units (0.075 mL))
Maintenance Dose
2.0 mg (2000 mcg) (30 units (0.30 mL))
Potential Benefits & Use Cases
Livagen is a research-use-only peptide not authorized for treating liver disease or dysfunction.
Inhibits enkephalin-degrading enzymes, potentially prolonging endogenous opioid signaling (preclinical)
Modulates gene expression and chromatin structure in aging tissues — heterochromatin decondensation (preclinical)
Supports cellular homeostasis and regenerative capacity (preclinical)
Normalized digestive enzyme activity toward youthful levels in aged rodents (preclinical)
Enhances hepatocyte protein synthesis and restores circadian biosynthesis rhythm (preclinical)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Regulates gene expression in thymic and immune-related tissues
→Stabilizes DNA structure and chromatin remodeling in aging cells
→Supports epigenetic regulation of nuclear protein synthesis
→Stimulates thymus-derived immune functions
Lifestyle & Optimization
timing
Consistent daily dosing.
diet
Balanced nutrient-dense diet.
exercise
Regular physical activity.
sleep
Quality sleep and stress management.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Mild digestive issues, slight headaches (user-reported)
Long-Term Safety Data
• Very limited safety data in humans
🧮 Dose Calculator
Concentration
66.7
mcg/unit
Draw Volume
7
units (0.070 mL)
For a 500 mcg dose, draw 7 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High systemic absorption and thymic tissue targeting via subcutaneous injection
Oral Administration
Not used due to poor stability and first-pass metabolism
Half-Life
Approximately 4 hours
Degradation
Metabolized via liver and renal peptidases
Tissue Specificity
Targets thymus, immune tissues, and nuclei of aging cells
⚗️
Peptide Details
Molecular Weight
467.57
Formula
C23H37N5O6
Sequence
Ala-Glu-Asp-Gly
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw